Determinants of glycemic control in type 2 diabetes mellitus in Brazil: A sub-analysis of the longitudinal data from the BrazIian type 1 &amp; 2 diabetes disease registry (BINDER)

Moreira, Rodrigo O.; Vianna, André Gustavo Daher; Ferreira, Graziela C.; Paula, Mauricio A. de

doi:10.1016/j.pcd.2022.04.003

Cited by 2 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Não houve diferença quanto ao uso dos diferentes antidiabéticos orais entre o basal e o seguimento, exceto para menor uso de metformina (p = 0,0044) e aumento do uso de inibidores de SGLT-2 (p < 0,001). 328 …”

Section: Conhecimento Tratamento E Controle Da Condiçãounclassified

See 1 more Smart Citation

Estatística Cardiovascular – Brasil 2023

Oliveira,

Brant,

Polanczyk

et al. 2024

Arquivos Brasileiros De Cardiologia

View full text Add to dashboard Cite

show abstract

Section: Conhecimento Tratamento E Controle Da Condiçãounclassified

“…In addition, the use of different oral antidiabetic drugs did not differ, except for a reduction in metformin use (p = 0.0044) and an increase in SGLT-2 inhibitors use (p < 0.001). 328 …”

Section: Knowledge Treatment and Control Of Diabetesmentioning

confidence: 99%

Estatística Cardiovascular – Brasil 2023

Oliveira,

Brant,

Polanczyk

et al. 2024

Arquivos Brasileiros De Cardiologia

View full text Add to dashboard Cite

show abstract

“…While the management of T2DM requires multiple interventions ranging from lifestyle modification, social policy, health system management, to public education, access to treatment is always the cornerstone of disease control [5][6][7][8]. The accessibility of advanced treatments among LMICs is limited due to the high cost of newer treatments [9]; thus, many LMICs, especially those in tropical regions, have attempted to uncover the pharmacological properties of native plants that have long been used for medicinal purposes [10].…”

Section: Introductionmentioning

confidence: 99%

Effects of turmeric (Curcuma longa) supplementation on glucose metabolism in diabetes mellitus and metabolic syndrome: An umbrella review and updated meta-analysis

Pathomwichaiwat,

Jinatongthai,

Prommasut

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

Aims This study aims to comprehensively review the existing evidence and conduct analysis of updated randomized controlled trials (RCTs) of turmeric (Curcuma longa, CL) and its related bioactive compounds on glycemic and metabolic parameters in patients with type 2 diabetes (T2DM), prediabetes, and metabolic syndrome (MetS) together with a sub-group analysis of different CL preparation forms. Methods An umbrella review (UR) and updated systematic reviews and meta-analyses (SRMAs) were conducted to evaluate the effects of CL compared with a placebo/standard treatment in adult T2DM, prediabetes, and MetS. The MEDLINE, Embase, The Cochrane Central Register of Control Trials, and Scopus databases were searched from inception to September 2022. The primary efficacy outcomes were hemoglobin A1C (HbA1C) and fasting blood glucose (FBG). The corrected covered area (CCA) was used to assess overlap. Mean differences were pooled across individual RCTs using a random-effects model. Subgroup and sensitivity analyses were performed for various CL preparation forms. Results Fourteen SRMAs of 61 individual RCTs were included in the UR. The updated SRMA included 28 studies. The CCA was 11.54%, indicating high overlap across SRMAs. The updated SRMA revealed significant reduction in FBG and HbA1C with CL supplementation, obtaining a mean difference (95% confidence interval [CI]) of –8.129 (–12.175, –4.084) mg/dL and –0.134 (–0.304, –0.037) %, respectively. FBG and HbA1C levels decreased with all CL preparation forms as did other metabolic parameters levels. The results of the sensitivity and subgroup analyses were consistent with those of the main analysis. Conclusion CL supplementation can significantly reduce FBG and HbA1C levels and other metabolic parameters in T2DM and mitigate related conditions, including prediabetes and MetS. Trial registration PROSPERO (CRD42016042131).

show abstract

Determinants of glycemic control in type 2 diabetes mellitus in Brazil: A sub-analysis of the longitudinal data from the BrazIian type 1 & 2 diabetes disease registry (BINDER)

Cited by 2 publications

References 19 publications

Estatística Cardiovascular – Brasil 2023

Estatística Cardiovascular – Brasil 2023

Effects of turmeric (Curcuma longa) supplementation on glucose metabolism in diabetes mellitus and metabolic syndrome: An umbrella review and updated meta-analysis

Contact Info

Product

Resources

About